(Q46231696)

20 December 2017

title

Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability (English)

1 reference

20 December 2017

author name string

Jessica C Brimecombe

series ordinal

1

1 reference

20 December 2017

Glenn E Kirsch

series ordinal

2

1 reference

20 December 2017

Arthur M Brown

series ordinal

3

1 reference

20 December 2017

publication date

8 November 2008

1 reference

20 December 2017

Journal of Pharmacological and Toxicological Methods

published in

1 reference

20 December 2017

volume

59

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

29-34

1 reference

20 December 2017

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Experiences in method development for the analysis of in vitro study solutions for content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Oral erythromycin and the risk of sudden death from cardiac causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Bioanalytical method validation--a revisit with a decade of progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

Arrhythmogenic mechanisms of non-sedating antihistamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.10.004

10.1016/J.VASCN.2008.10.004

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017